• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predictors of response and resistance to checkpoint inhibitors in solid tumors.

作者信息

Rao Sanjana V, Moran Amy E, Graff Julie N

机构信息

Oregon Health & Science University School of Medicine, Portland, OR, USA.

Department of Cell, Developmental & Cancer Biology, Portland, OR, USA.

出版信息

Ann Transl Med. 2017 Dec;5(23):468. doi: 10.21037/atm.2017.09.35.

DOI:10.21037/atm.2017.09.35
PMID:29285501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5733326/
Abstract
摘要

相似文献

1
Predictors of response and resistance to checkpoint inhibitors in solid tumors.实体瘤中检查点抑制剂反应和耐药性的预测指标
Ann Transl Med. 2017 Dec;5(23):468. doi: 10.21037/atm.2017.09.35.
2
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.接受检查点抑制剂治疗的实体瘤患者选择的临床特征和影像预测结果。
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325. doi: 10.1007/s00259-017-3802-5. Epub 2017 Aug 16.
3
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.转移性结直肠癌中免疫检查点抑制剂原发性耐药与微卫星不稳定性或错配修复缺陷状态误诊的关联。
JAMA Oncol. 2019 Apr 1;5(4):551-555. doi: 10.1001/jamaoncol.2018.4942.
4
Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.激酶抑制剂联合免疫检查点抑制剂治疗实体瘤的临床潜力。
Int J Mol Sci. 2021 Mar 5;22(5):2608. doi: 10.3390/ijms22052608.
5
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.免疫检查点抑制剂在结直肠癌治疗中的出现。
Curr Drug Targets. 2021;22(9):1021-1033. doi: 10.2174/1389450122666210204204415.
6
-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors.紫杉醇作为实体瘤中与检查点抑制剂联用的潜在药物。
Onco Targets Ther. 2016 Dec 21;10:101-112. doi: 10.2147/OTT.S122974. eCollection 2017.
7
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.每兆碱基 10 个或更多突变的微卫星稳定实体瘤对抗 PD-1 免疫治疗的反应率。
JAMA Oncol. 2021 May 1;7(5):739-743. doi: 10.1001/jamaoncol.2020.7684.
8
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.基于 CT 的放射组学特征与晚期实体瘤免疫检查点抑制剂治疗反应相关。
Radiology. 2021 Apr;299(1):109-119. doi: 10.1148/radiol.2021200928. Epub 2021 Jan 26.
9
Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors.肥大细胞和树突状细胞作为实体瘤免疫治疗中的细胞免疫检查点。
Int J Mol Sci. 2022 Sep 21;23(19):11080. doi: 10.3390/ijms231911080.
10
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.新型检查点抑制剂正在研发中：靶向实体瘤中的TIM-3
Curr Oncol Rep. 2022 May;24(5):651-658. doi: 10.1007/s11912-022-01218-y. Epub 2022 Feb 26.

引用本文的文献

1
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.黑色素瘤中抗PD-1免疫疗法的耐药机制及克服策略
Biomolecules. 2025 Feb 12;15(2):269. doi: 10.3390/biom15020269.
2
Proteome and phosphoproteome signatures of recurrence for HPV head and neck squamous cell carcinoma.人乳头瘤病毒相关头颈部鳞状细胞癌复发的蛋白质组和磷酸化蛋白质组特征
Commun Med (Lond). 2022 Jul 30;2:95. doi: 10.1038/s43856-022-00159-8. eCollection 2022.
3
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.黑色素瘤对免疫肿瘤学检查点抑制剂治疗的耐药机制。
Cancer Drug Resist. 2019 Sep 19;2(3):744-761. doi: 10.20517/cdr.2019.28. eCollection 2019.
4
Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors.基于深度学习的身体成分分析可预测接受免疫检查点抑制剂治疗的黑色素瘤患者的预后。
Diagnostics (Basel). 2021 Dec 9;11(12):2314. doi: 10.3390/diagnostics11122314.
5
Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.FcγRIIB、微生物组和检查点抑制剂在抗肿瘤免疫中的交汇。
Cancer Immunol Immunother. 2021 Dec;70(12):3397-3404. doi: 10.1007/s00262-021-03004-4. Epub 2021 Jul 9.
6
Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.冷冻消融与免疫治疗乳腺癌：联合治疗的概述与原理。
Radiol Imaging Cancer. 2021 Feb 26;3(2):e200134. doi: 10.1148/rycan.2021200134. eCollection 2021 Mar.
7
Checking autoimmune genetic risk to stratify immune checkpoint inhibitor responders.检查自身免疫遗传风险以对免疫检查点抑制剂反应者进行分层。
Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):13864-13866. doi: 10.1073/pnas.2007744117. Epub 2020 Jun 5.

本文引用的文献

1
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.实体瘤中程序性细胞死亡蛋白1（PD-1）配体（PD-L1）的表达作为从PD-1/PD-L1轴抑制剂中获益的预测生物标志物：一项系统评价和荟萃分析
JCO Precis Oncol. 2017 Nov;1:1-15. doi: 10.1200/PO.16.00030.
2
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.基线β-连环蛋白、程序性死亡配体1表达和肿瘤浸润淋巴细胞可预测BRAF抑制剂治疗的黑色素瘤患者的反应及不良预后。
Eur J Cancer. 2017 Jun;78:70-81. doi: 10.1016/j.ejca.2017.03.012. Epub 2017 Apr 14.
3
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.基线肠道微生物群可预测接受伊匹单抗治疗的转移性黑色素瘤患者的临床应答和结肠炎。
Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108.
4
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.对连续进行CTLA-4和PD-1阻断治疗的肿瘤活检组织进行综合分子分析，揭示了反应和耐药的标志物。
Sci Transl Med. 2017 Mar 1;9(379). doi: 10.1126/scitranslmed.aah3560.
5
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.肿瘤微环境抑制T细胞线粒体生物合成，导致肿瘤内T细胞代谢不足和功能障碍。
Immunity. 2016 Sep 20;45(3):701-703. doi: 10.1016/j.immuni.2016.08.009.
6
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.与黑色素瘤中PD-1阻断获得性耐药相关的突变
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
7
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.帕博利珠单抗治疗黑色素瘤患者预后的基线生物标志物
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16.
8
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.克隆性新抗原引发T细胞免疫反应性以及对免疫检查点阻断的敏感性。
Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.
9
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.对治疗性程序性死亡蛋白1（PD-1）阻断的适应性耐药与其他免疫检查点的上调相关。
Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501.
10
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.PTEN缺失促进对T细胞介导的免疫疗法的抗性。
Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.